Figure 2
From: Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival
Association between mutational and neoepitope landscapes. BLCA mutanomes were analyzed with Ancer to determine counts of Ancer-defined HLA class I neoepitopes (a), Ancer-defined HLA class II neoepitopes (b), and Ancer-defined neoantigen candidates that could be used for precision immunotherapy purposes (c). Numbers of HLA class I neoepitopes, HLA class II neoepitopes, and neoantigen candidates observed in each patient is strongly correlated with observed tumor mutational burden (TMB). Each dot corresponds to one TGCA BLCA patient.
